Free Newsletter
Breakthrough on influenza vaccine
Japanese researchers have developed a new approach to make flu vaccines that are able to combat multiple strains of influenza, including strains of the bird flu virus, according to Japan's National Institute of Infectious Diseases. The advance centers on their ability to develop a peptide based on the influenza virus with an antigen on the surface which triggers an immune response. The new approach is distinct from current vaccines, which create antibodies that target influenza. As the surface of the virus mutates it can escape detection by the current generation of vaccines. This new approach targets the inside of a virus rather than its surface. And the researchers, led by Tetsuya Uchida, tested the new approach on mice infected with multiple strains of influenza.
Tetsuya noted that a new vaccine frequently takes about five years to develop. But he added that with the current alarm over a possible outbreak of bird flu among humans, a more rapid development program could be put into place. More than 200 people have died from bird flu to date.
- read the report from News-Medical
- and here's the story from AFP
ALSO: India is fighting a new bird flu outbreak in birds in West Bengal. Report
Related Articles:
Breakthrough reported in flu vaccine research. Report
Breakthrough in understanding mechanism of bird flu. Report
Experimental vaccines show efficacy against H5N1 viruses. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: